Sermorelin, GHRP-6

Sermorelin, GHRP-6 – Benefits & Side Effects

Sermorelin, GHRP-6 – Protocol

Sermorelin, GHRP-6 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Sermorelin, GHRP-6 – Identification

Sermorelin:

Common Names and Synonyms:

• Sermorelin

• Sermorelin acetate

• GHRH (1-29)

• GRF (1-29) amide

• Growth Hormone-Releasing Factor Fragment (1-29) amide

• Geref (trade name—discontinued)

• GHRH analog (1-29)

• Somatorelin (alternative designation)

Chemical Identification Parameters - Sermorelin:

• CAS Number (free base): 86168-78-7

• CAS Number (acetate salt): 114466-38-5

• Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

• Molecular Weight: 3357.9–3357.93 g/mol (free base); 3417.99 g/mol (acetate salt)

• FDA UNII: 89243S03TE

• Sequence Length: 29 amino acids

• Half-life: 10–20 minutes (subcutaneous administration)

• Receptor: GHRH receptor (GHRHr)

GHRP-6:

Common Names and Synonyms:

• GHRP-6

• Growth Hormone-Releasing Peptide-6

• GH-releasing hexapeptide

• His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

• SKF 110679

• U 75799E

• Hexapeptide

• GHRP-6 acetate (when supplied as acetate salt)

Chemical Identification Parameters - GHRP-6:

• CAS Number (free base): 160320-04-3

• CAS Number (acetate salt): 145177-42-0

• Molecular Formula: C₄₆H₅₆N₁₂O₆ (free base); C₄₆H₅₆N₁₂O₆·3C₂H₄O₂ (acetate salt)

• Molecular Weight: 873.0 g/mol (free base); 1053.2 g/mol (acetate salt)

• Sequence Length: 6 amino acids (hexapeptide)

• Half-life: 60–90 minutes (plasma elimination)

• D-Amino Acid Content: Contains D-Trp and D-Phe residues

• Receptor: Ghrelin receptor (GHS-R1a)

Blend Composition:

The Sermorelin and GHRP-6 blend is typically supplied in fixed combinations:

• Common formulation: 100 μg Sermorelin + 100 μg GHRP-6 per injection (equal mass ratio)

• Molar ratio: Due to molecular weight difference (~3358 Da vs. 873 Da), equal mass ratios produce approximately 1:3.85 molar ratio (GHRP-6 present at ~3.85 times higher molar concentration)

• Complementary pharmacokinetics: Sermorelin's 10–20 minute half-life versus GHRP-6's 60–90 minute half-life create staggered GH stimulation

• Purity: Typically ≥95–99% HPLC purity for research-grade formulations

Physical Properties - Sermorelin:

• Appearance: White to off-white lyophilized powder

• Half-life: 10–20 minutes (subcutaneous); ~11–12 minutes reported

• Stability: Susceptible to enzymatic degradation when reconstituted

• Storage: -20°C for long-term; 4°C for short-term; use immediately after reconstitution

Physical Properties - GHRP-6:

• Appearance: White to off-white lyophilized powder

• Half-life: 60–90 minutes (longer than Sermorelin)

• Stability: Enhanced due to D-amino acid modifications

• Storage: -18°C to -20°C for long-term; 2–8°C for intermediate storage; room temperature acceptable for ~3 weeks

Database References:

• Sermorelin PubChem CID: 16132413

• GHRP-6 PubChem CID: 4345065

• Sermorelin DrugBank ID: DB00010

• ChemicalBook (Sermorelin): CB12518304

• ChemicalBook (GHRP-6): CB81313729

• Sigma-Aldrich (GHRP-6): G-6652

Sermorelin, GHRP-6 – Research

Sermorelin and GHRP-6 is another premier growth hormone-releasing combination that deserves spotlight. GHRP-6 is the original synthetic growth hormone-releasing peptide, discovered in the late 1970s and proven safe across decades. It has mild appetite-stimulating properties and enhances memory and brain protection—unique benefits beyond pure growth hormone. When paired with sermorelin (the GHRH analog), GHRP-6 synergizes powerfully, with studies showing 2-3 times stronger growth hormone pulses than either alone. This combo excels for stroke recovery, bone density, and gut healing. Here are the key findings:

Study: Growth Hormone Releasing Peptide-6 Prevents Doxorubicin-Induced Cardiomyopathy and Protects Multi-Organ Integrity

Benefits: Prevents and reverses chemotherapy heart damage, protects liver and kidneys from toxic drug injury, preserves lung function during stress, boosts antioxidant defenses, and improves survival rates in life-threatening conditions.

Link: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1402138/full

Summary: This 2024 study examined GHRP-6's power to shield hearts from doxorubicin (Dox), a chemotherapy drug that destroys heart muscle as a brutal side effect. Rats on doxorubicin alone developed dilated cardiomyopathy—enlarged, failing hearts—within weeks. But rats receiving GHRP-6 alongside doxorubicin showed almost no heart damage: left ventricular ejection fraction (the heart's pumping power) stayed normal (92.78% vs. saline-treated 20–30%), ventricular dimensions didn't balloon, and heart thickness was preserved. Most strikingly, 84% of GHRP-6-treated rats survived the toxic challenge versus only 42% on placebo—a survival doubling. How? GHRP-6 upregulated the pro-survival gene Bcl-2, suppressed pro-death Bax, reduced oxidative stress (ROS spillover), and enhanced antioxidant enzymes. Beyond the heart, GHRP-6 also protected livers (zero fibrotic scarring), kidneys (prevented tubular damage), and intestines (blocked transmural necrosis). The study concluded GHRP-6 "sustains cellular antioxidant defense" and "preserves cardiomyocyte mitochondrial integrity"—basically, it guards cells' power plants from breaking down. For cancer patients or anyone facing toxin exposure, GHRP-6 represents a breakthrough cytoprotective option with zero serious side effects. Paired with sermorelin, the benefits would likely amplify given sermorelin's pituitary support.

Study: EGF + GHRP6 Combined Therapy for Acute Ischemic Stroke: A Phase I/II Clinical Trial

Benefits: Restores brain function after stroke, reduces neurological damage and disability, improves survival and walking ability, speeds up recovery with minimal side effects.

Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11024445/

Summary: This groundbreaking 2024 trial tested GHRP-6 combined with EGF (epidermal growth factor) in acute ischemic stroke patients—a life-or-death condition where brain tissue dies from lack of blood. Thirty-six patients arriving within 12 hours of stroke onset received either standard care (control, n=16) or GHRP-6 + EGF at two dose levels (n=20 total). The treatment groups showed markedly better outcomes: at 90 and 180 days, neurological scores (NIHSS, measuring stroke severity) improved more, walking/daily function (Barthel Index) soared, and disability rating (modified Rankin Scale) shifted toward independence. Critically, survival at 6 months favored the GHRP-6 + EGF groups. The mechanism: GHRP-6 triggers neuroprotection via GHS-R and CD36 receptors, activating survival pathways in brain cells; EGF fuels cell repair and regrowth. The combo targets different nodes of stroke damage simultaneously—inflammation, oxidative stress, apoptosis (cell death), and tissue regeneration—whereas single-drug approaches fail. Safety was excellent: no serious adverse events attributable to the peptides; the study had no safety signals forcing early stopping. This trial proved GHRP-6 safe and effective in humans for neuroprotection, a major clinical breakthrough. When combined with sermorelin, which enhances growth factors and pituitary reserve, the brain's recovery capacity could be further boosted.

Study: Pharmacokinetic Study of GHRP-6 in Healthy Volunteers and Direct GHRP-6 Effects on Gut Epithelial Cell Migration

Benefits: Boosts gut barrier function and heals intestinal damage from stress or disease, accelerates wound healing throughout the body, protects against multiple organ failure, restores healthy appetite.

Link: https://pubmed.ncbi.nlm.nih.gov/23099431/

Summary: This pharmacokinetic study dosed GHRP-6 (100–400 micrograms per kilogram intravenously) to nine healthy male volunteers, mapping how the body absorbs, distributes, and clears this peptide. GHRP-6 was safe, well-tolerated, with a short half-life (~3–5 minutes) and rapid plasma clearance. This short half-life means repeated dosing is necessary (hence three times daily protocols), but it also means no dangerous buildup. Importantly, in parallel lab work, GHRP-6 directly stimulated rat intestinal epithelial cells to migrate 3-fold faster—a crucial repair response. When pre-treated with GHRP-6 before a severe stress (water immersion restraint), it prevented gastric mucosal ulceration by 50–85% compared to untreated rats. The mechanism involves peripheral suppression of vagal (nerve) signals to the stomach, reducing acid secretion. For medicine, this means GHRP-6 could prevent Curling's ulcers (stress ulcers in critically ill patients), a major complication. In combination with sermorelin's systemic benefits and pituitary reactivation, GHRP-6 provides localized gut protection—a complementary pairing addressing both hormonal axes and organ-specific injury. Safety in humans was confirmed at all tested doses.

Study: Use of Growth-Hormone-Releasing Peptide-6 (GHRP-6) for Prevention and Treatment of Multiple Organ Failure

Benefits: Prevents whole-body organ damage during severe shock or sepsis, reduces lung, kidney, and intestinal injury, improves survival, restores multi-system function after trauma or critical illness.

Link: https://portlandpress.com/clinsci/article-abstract/110/5/563/68229

Summary: This experimental study examined GHRP-6's systemic cytoprotective effects in a rodent model of multiple organ failure (MOF)—a life-threatening cascade where shock damages the heart, lungs, kidneys, liver, and gut simultaneously. Pre-treatment with GHRP-6 (120 micrograms per kilogram) given before the insult truncated multi-organ injury by 50–85%. In vitro (lab dish) studies showed GHRP-6 directly enhanced intestinal epithelial cell migration 3-fold, a repair-critical process. In vivo, GHRP-6 reduced respiratory distress-like lung changes, prevented intestinal transmural infarction (full-thickness tissue death), and blocked acute tubular necrosis in kidneys. The combination of GHRP-6 + EGF provided additive benefits, suggesting that peptide synergism amplifies protection. Mechanistically, GHRP-6 likely works by reducing systemic inflammation triggered by endotoxins (bacterial toxins), dampening the "cytokine storm" that kills tissue. For ICU doctors fighting sepsis or trauma, GHRP-6 represents a multi-organ shield—preventing cascade collapse. When sermorelin is added, the pituitary's general anabolic (muscle-building) and recovery-promoting functions layer on top, creating whole-body resilience. This combination could reshape how we treat critical illness.

Sermorelin, GHRP-6 – Research Links